DRKS00022507招募中不适用
Patients with Breast Cancer in Times of COVID-19 - MaZeCO
niversitätsklinikum Würzburg, Frauenklinik und Poliklinik0 个研究点目标入组 200 人开始时间: 2020年7月22日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 80 Years（—）
- 性别
- Female
入选标准
- •breast cancer patients, sufficient German language skills, ability of consent
排除标准
- •no consent, revocation of consent
研究者
相似试验
尚未招募
不适用
Effect Of COVID-19 on breast cancer treatment and its outcomeCTRI/2020/11/028969A
已完成
不适用
COVID-19 pandemic and breast cancer management: An observational clinical study from PakistaCOVID-19C50Malignant neoplasm of breastDRKS00023807Aga Khan University112
尚未招募
3 期
Perspective of cancer patient in COVID-19 pandemicCTRI/2020/10/028438nil
已完成
不适用
Epirubicin/Paclitaxel/Cyclophosphamide-Methotrexate-Fluorouracil (E-T-CMF) as adjuvant chemotherapy in high-risk patients with operable breast cancerCancer - BreastBreast CancerACTRN12615000161527Hellenic Cooperative Oncology Group1,000
已完成
不适用
Investigation of the prognostic role of protein expression, mRNA levels, gene amplification and mutation of key cellular elements in patients with breast cancer treated with dose-dense sequential adjuvant chemotherapyCancer - BreastBreast CancerACTRN12616001043426Hellenic Cooperative Oncology Group1,060